by | Jun 13, 2026 | Uncategorized
FDA approved baxdrostat (Baxfendy) on May 18, 2026 as the first-ever oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension. BaxHTN Phase 3 (NEJM 2025): 8.7–9.8 mmHg additional systolic blood pressure reduction added to background therapy....
by | Jun 13, 2026 | Uncategorized
A comprehensive June 2026 guide to Alzheimer’s prevention and treatment: two FDA-approved disease-modifying drugs (lecanemab/Leqembi, donanemab/Kisunla), an FDA-cleared blood test (Lumipulse pTau217), and the lifestyle interventions with the strongest prevention...
by | Jun 13, 2026 | Uncategorized
The CDC has an active warning about harmful and potentially fatal reactions from counterfeit Botox and mishandled botulinum toxin injections, documented across multiple U.S. states. A 2024 investigation found 22 hospitalizations, including 4 on ventilators. The CDC...
by | Jun 13, 2026 | Uncategorized
The RUBY Trial (NEJM, April 2026): CRISPR-Cas12a gene editing therapy reni-cel (renizgamglogene autogedtemcel) achieved a functional cure in 27 of 28 (96%) severe sickle cell disease patients, with no painful crises for up to two years after treatment. Led by Dr. Rabi...
by | Jun 13, 2026 | Uncategorized
The FDA and CDC declared the ByHeart infant formula botulism outbreak over on February 26, 2026 after 48 infants were sickened across 17 states. A June 10, 2026 Food Safety Magazine investigation reveals the root cause remains unidentified despite genetic matches to...
Recent Comments